Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients

详细信息    查看全文

• 作者：Yan Sun ; Xinmin Yu ; Xun Shi ; Wei Hong ; Jun Zhao…
• 关键词：Lung adenocarcinoma ; IASLC/ATS/ERS classification ; Stage IB ; Prognosis ; EGFR mutation
• 刊名：World Journal of Surgical Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：12
• 期：1
• 全文大小：383 KB
• 参考文献：1. Siegel, R, Naishadham, D, Jemal, A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: pp. 11-30 CrossRef
  2. Li, Z, Yu, Y, Lu, J, Luo, Q, Wu, C, Liao, M, Zheng, Y, Ai, X, Gu, L, Lu, S (2009) Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J ThoracOncol 4: pp. 702-709
  3. Travis, WD, Brambilla, E, Noguchi, M, Nicholson, AG, Geisinger, KR, Yatabe, Y, Beer, DG, Powell, CA, Riely, GJ, Van Schil, PE, Garg, K, Austin, JH, Asamura, H, Rusch, VW, Hirsch, FR, Scagliotti, G, Mitsudomi, T, Huber, RM, Ishikawa, Y, Jett, J, Sanchez-Cespedes, M, Sculier, JP, Takahashi, T, Tsuboi, M, Vansteenkiste, J, Wistuba, I, Yang, PC, Aberle, D, Brambilla, C, Flieder, D (2011) The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol 6: pp. 244-285 CrossRef
  4. Woo, T, Okudela, K, Mitsui, H, Tajiri, M, Yamamoto, T, Rino, Y, Ohashi, K, Masuda, M (2012) Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. PatholInt 62: pp. 785-791
  5. Gu, J, Lu, C, Guo, J, Chen, L, Chu, Y, Ji, Y, Ge, D (2013) Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J SurgOncol 107: pp. 474-480
  6. Russell, PA, Barnett, SA, Walkiewicz, M, Wainer, Z, Conron, M, Wright, GM, Gooi, J, Knight, S, Wynne, R, Liew, D, John, T (2013) Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J ThoracOncol 8: pp. 461-468
  7. Yoshizawa, A, Motoi, N, Riely, GJ, Sima, CS, Gerald, WL, Kris, MG, Park, BJ, Rusch, VW, Travis, WD (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24: pp. 653-664 CrossRef
  8. Mitsudomi, T, Morita, S, Yatabe, Y, Negoro, S, Okamoto, I, Tsurutani, J, Seto, T, Satouchi, M, Tada, H, Hirashima, T, Asami, K, Katakami, N, Takada, M, Yoshioka, H, Shibata, K, Kudoh, S, Shimizu, E, Saito, H, Toyooka, S, Nakagawa, K, Fukuoka, M (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: pp. 121-128 CrossRef
  9. Maemondo, M, Inoue, A, Kobayashi, K, Sugawara, S, Oizumi, S, Isobe, H, Gemma, A, Harada, M, Yoshizawa, H, Kinoshita, I, Fujita, Y, Okinaga, S, Hirano, H, Yoshimori, K, Harada, T, Ogura, T, Ando, M, Miyazawa, H, Tanaka, T, Saijo, Y, Hagiwara, K, Morita, S, Nukiwa, T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: pp. 2380-2388 CrossRef
  10. Shepherd, FA, Rodrigues Pereira, J, Ciuleanu, T, Tan, EH, Hirsh, V, Thongprasert, S, Campos, D, Maoleekoonpiroj, S, Smylie, M, Martins, R, van Kooten, M, Dediu, M, Findlay, B, Tu, D, Johnston, D, Bezjak, A, Clark, G, Santabárbara, P, Seymour, L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: pp. 123-132 CrossRef
  11. Mok, TS, Wu, YL, Thongprasert, S, Yang, CH, Chu, DT, Saijo, N, Sunpaweravong, P, Han, B, Margono, B, Ichinose, Y, Nishiwaki, Y, Ohe, Y, Yang, JJ, Chewaskulyong, B, Jiang, H, Duffield, EL, Watkins, CL, Armour, AA, Fukuoka, M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: pp. 947-957 CrossRef
  12. Lynch, TJ, Bell, DW, Sordella, R, Gurubhagavatula, S, Okimoto, RA, Brannigan, BW, Harris, PL, Haserlat, SM, Supko, JG, Haluska, FG, Louis, DN, Christiani, DC, Settleman, J, Haber, DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: pp. 2129-2139 CrossRef
  13. Yoshizawa, A, Sumiyoshi, S,
• 刊物主题：Surgical Oncology;
• 出版者：BioMed Central
• ISSN：1477-7819

文摘

Background A new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) has recently been published. This study aimed to investigate the utility of the new histological classification for identifying the prognostic subtypes of adenocarcinomas in stage IB patients.Correlations between the classification and the presence of epidermal growth factor receptor (EGFR) mutation status was also studied. Methods One hundred and thirty-six patients with stage IB lung adenocarcinoma operated on in Zhejiang Cancer Hospital were identified between 2002 and 2011. Patients overall survival and disease-free survival were calculated using Kaplan-Meier and Cox regression analyses. EGFR mutations were detected using the amplification refractory mutation system. Results A total of 136 cases were included in current study, of which 38 were papillary predominant, 39 were acinar predominant, 22 were micropapillary predominant, 21 were lepidic predominant subtypes, 14 were solid predominant, and 2 were variants of invasive adenocarcinoma. Patients with micropapillary- and solid-predominant tumors had the lowest five-year disease-free survival (28.4 and 36.7%, respectively). Univariate and multivariate analysis showed that the micropapillary-predominant subtype was an independent predictor of disease-free survival (P--.0041 and 0.048, respectively), but not overall survival (P--.175 and 0.214, respectively). EGFR mutations were significantly associated with the micropapillary-predominant subtype patients (P--.0026). The EGFR mutation frequency is lower in the solid-predominant subtype than other subtypes (P--.0508). Conclusions The predominant subtype in the primary tumor was associated with prognosis in resected stage IB lung adenocarcinoma. The EGFR mutation frequency of micropapillary-predominant subtype is higher than other subtypes.